Evidence map›Paper›PMID 40990254›Full record

ArticleFuture science OA2025

Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.

Hanjie Zhang, Kaiqiang Tang, Yiyang Chen, Guoqiang Chen, Geli Tan, Yiyu Dong, Jingwen Ling, Rongquan He, Diyuan Qin, Juan He and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hanjie ZhangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Kaiqiang TangDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yiyang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guoqiang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Geli TanDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yiyu DongDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jingwen LingDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Rongquan HeDepartment of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Diyuan QinDepartment of Computer Science and Technology, School of Computer and Electronic Information, Guangxi University, Nanning, China.
Juan HeDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shenghua LiDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yiwu DangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhenbo FengDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lili DengDepartment of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to investigate the expression profile, molecular mechanisms, and biological functions of Connective Tissue Growth Factor (CTGF) in bladder cancer (BLCA).

methodsFor accurate CTGF mRNA expression assessment, 1728 samples were collected. Additionally, for uncovering potential signaling pathways, differentially co-expressed CTGF genes were employed. For exploring CTGF's effects, its impact on immune microenvironment and drug sensitivity was studied.

resultsCTGF mRNA was significantly underexpressed in BLCA (standardized mean difference [SMD] = -1.06, 95% CI: -1.89-0.23), and this downregulation was confirmed at the protein level (

conclusionsThis study elucidated the low expression of CTGF in BLCA. CTGF may promotes tumor progression by remodeling the immune microenvironment and extracellular matrix. Additionally, its expression is positively correlated with sensitivity to EGFR inhibitors and negatively correlated with resistance to PARP inhibitors.

Indexed as

CTGFdrug sensitivityGene expressionimmune microenvironmentmolecular mechanism

Identifiers

PMID40990254
PMCPMC12461894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.